Pfizer’s decision to halt Exubera inhaled insulin sales has led the layoff of 660 of the drug company’s workers at its Terre Haute, Indiana manufacturing facility.
The news was announced by Nat Ricciardi, president of Pfizer Global Manufacturing. Workers were informed that they would lose their jobs today, according to the Kalamazoo Gazette.
That will leave more time for MySpace postings by current, former, and soon-to-be terminated Pfizer Exubera manufacturing facility employees who were known to share their personal information with folks on the world wide web!
Folks like young Exubera worker Justin Mattick who, for more than a year, has been happy to let Pfizer, competing drugmakers, and neighbors know that he makes $75,000 - $100,000 a year.
Then there was Adam Gentry who once said that Pfizer’s Terre Haute Exubera production plant “has a slower work pace (mind-numbingly slow at times).” Gentry also disclosed details about Pfizer’s quality control procedures, advising that “[b]ecause they’re regulated by the FDA, EU, UK, ASCAP, UCLA, KFC, etc, we have to be very careful and sign everything.”
Readers shouldn’t forget that another apparent Pfizer insider (”I actually work for Pfizer,” the insider admitted) who publicly alleged that “[t]here are several issues with the manufacturing process that I will not go into, but lets just say it’s not efficient or effective.”
Novo’s AERX inhaled insulin was in 